Pro Pharmaceuticals Group (Australia)

Pro Pharmaceuticals Group, a specialty pharmaceutical company, focuses on sourcing and licencing products to meet medical needs. Over the last 3 years we have grown our customer base, products and suppliers. Pro Pharmaceuticals Group is a privately owned company was founded in 2015 and is headquartered in Melbourne, Australia.

Related News

TSCAN AND NOVARTIS PARTNER TO DEVELOP CANCER THERAPIES

Pharmaceutical Technology | April 16, 2020

news image

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer. The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments. As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets. Furthermore, Novartis wil...

Read More

PHARMA TECH

AQUAVIT FURTHER PREVAILS AGAINST COUNTERFEITERS IN U S FOLLOWING ITS RECENT VICTORY IN EUROPE

Aquavit Pharmaceuticals, Inc | March 22, 2022

news image

Aquavit Pharmaceuticals, Inc continues to succeed in its intellectual property cases against counterfeiters both domestically and abroad. Following a recent win against counterfeiter U-BioMed, Inc. across the European Union, the U.S. Southern District Court of New York adopted Judge Lehrburger's recommendations that any sanctions related to U-BioMed's deletion of its Instagram account, which blatantly exploited Aquavit's AQUAGOLD product illegally, be folded into the p...

Read More

BUSINESS INSIGHTS

MATRIC TO ESTABLISH FIRST AND ONLY NATIONAL CENTER OF EXCELLENCE FOR PHARMACEUTICAL PROCESS DESIGN

The Mid-Atlantic Technology, | March 03, 2022

news image

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...

Read More

BUSINESS INSIGHTS

ACORDA THERAPEUTICS AND BIOPAS LABORATORIES ANNOUNCE AGREEMENT TO COMMERCIALIZE INBRIJA® IN LATIN AMERICA

Acorda Therapeutics, Inc. | May 12, 2022

news image

Acorda Therapeutics, Inc. and Biopas Laboratorie announced that they have entered into distribution and supply agreements to commercialize INBRIJA® in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. Under the terms of the agreements, Acorda will receive a significant, double-digit, tiered percentage of ...

Read More
news image

TSCAN AND NOVARTIS PARTNER TO DEVELOP CANCER THERAPIES

Pharmaceutical Technology | April 16, 2020

Biopharmaceutical firm TScan Therapeutics has signed an agreement with Novartis to discover and develop therapies for the treatment of cancer. The companies aim to work on TCR-engineered T-cell therapies for solid tumours. TScan’s platform will identify cancer antigens that could be targeted by TCR-based treatments. As part of the deal, TScan will find and characterise TCRs while Novartis will hold an option to licence and develop TCRs for up to three new targets. Furthermore, Novartis wil...

Read More
news image

PHARMA TECH

AQUAVIT FURTHER PREVAILS AGAINST COUNTERFEITERS IN U S FOLLOWING ITS RECENT VICTORY IN EUROPE

Aquavit Pharmaceuticals, Inc | March 22, 2022

Aquavit Pharmaceuticals, Inc continues to succeed in its intellectual property cases against counterfeiters both domestically and abroad. Following a recent win against counterfeiter U-BioMed, Inc. across the European Union, the U.S. Southern District Court of New York adopted Judge Lehrburger's recommendations that any sanctions related to U-BioMed's deletion of its Instagram account, which blatantly exploited Aquavit's AQUAGOLD product illegally, be folded into the p...

Read More
news image

BUSINESS INSIGHTS

MATRIC TO ESTABLISH FIRST AND ONLY NATIONAL CENTER OF EXCELLENCE FOR PHARMACEUTICAL PROCESS DESIGN

The Mid-Atlantic Technology, | March 03, 2022

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...

Read More
news image

BUSINESS INSIGHTS

ACORDA THERAPEUTICS AND BIOPAS LABORATORIES ANNOUNCE AGREEMENT TO COMMERCIALIZE INBRIJA® IN LATIN AMERICA

Acorda Therapeutics, Inc. | May 12, 2022

Acorda Therapeutics, Inc. and Biopas Laboratorie announced that they have entered into distribution and supply agreements to commercialize INBRIJA® in Latin America. INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. Under the terms of the agreements, Acorda will receive a significant, double-digit, tiered percentage of ...

Read More